Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study.
OBJECTIVE
To evaluate the efficacy of the probiotic yeast Saccharomyces boulardii (S. boulardii) as an adjuvant to oral rehydration solution (ORS) in shortening the duration of acute infectious gastroenteritis in children less than 2 years old in ambulatory care.


METHODS
In a period of 1 year, 100 outpatients between 3 and 24 months old presenting with acute mild to moderate diarrhoea of less than 7 days duration, were included in a double-blind, randomized, placebo-controlled trial evaluating the efficacy of S. boulardii administered for 6 days. Twelve children were lost in follow-up; the data of 88 children could be analysed (44 in the placebo and 44 in the S. boulardii group). Seventy-two patients were followed for one month (37 in the placebo and 35 in the S. boulardii group) allowing the calculation of the duration of diarrhoea.


RESULTS
The mean duration of diarrhoea was 6.16 days (range 2-13 days) in the placebo group and 4.70 days (range 2-10 days) in the S. boulardii group (p<0.05). On the 4th day, the patients in the S. boulardii group passed 2.5+/-1.4 stools/day versus 3.5+/-1.8 in the placebo group (p<0.001). The risk of having diarrhoea lasting more than 7 days was lower in the S. boulardii group (3/44 versus 12/44; RR 0.25; 95% CI 0.1-0.8). In no patient diarrhoea persisted longer than 14 days. A statistically significant difference was observed in the number of stools on the 4th and 7th day favouring the subgroup that received early treatment (within the first 48 h of the onset of diarrhoea). The administration of antibiotics before inclusion did not make any difference.


CONCLUSIONS
S. boulardii as an adjuvant to ORS in ambulatory care in children less than 2 years old with mild or moderate acute diarrhoea decreased the duration of diarrhoea, accelerated recovery and reduced the risk of prolonged diarrhoea. The data also indicate increased efficacy if S. boulardii is administered within the first 48 h of the onset of diarrhoea.
Villarruel
Gladys
G
Hospital Privado Materno Infantil, National University of Salta, Campo Castañares, Salta, Argentina.
Rubio
Daniel Martinez
DM
Lopez
Fani
F
Cintioni
Julio
J
Gurevech
Rubén
R
Romero
Gladis
G
Vandenplas
Yvan
Y
D003131:Combined Modality Therapy; D004311:Double-Blind Method; D004403:Dysentery / Q000628:therapy*; D005260:Female; D005440:Fluid Therapy; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D019936:Probiotics / Q000008:administration & dosage / Q000627:therapeutic use*; D012440:Saccharomyces; D013997:Time Factors; D016896:Treatment Outcome